ClinicalTrials.gg
CompletedNCT03417505Updated Jan 18, 2020Results posted

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

An interventional study of Scleral lenses treated with Tangible Hydra-PEG and Untreated scleral lenses in Dry Eye and Dry Eye Syndromes, sponsored by Tangible Science. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Tangible Science · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
393rd of 473
21 · median 60
Started
2018
with 35 others
No phase
136 of 544
10 open now
Registered
256th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 393rd largest by enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2018, is one of 136 with no phase, and was the 256th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.

Read the detailed description

Dry eye (DE) is a common complaint of millions of people worldwide with a significant impact on quality of life. For decades, this condition has presented a challenge to eye care professionals as conventional therapies are often ineffective. Recently, scleral lenses have demonstrated to be a promising therapeutic and vision rehabilitative option for dry eye sufferers. Nonetheless, despite the benefits of scleral lenses for dry eye patients, inadequate wettability of scleral lenses with subsequent diminished comfort and visual clarity remains a concern for scleral lens wearers with dry eye.

Tangible Hydra-PEG (Tangible Science LLC, Menlo Park, CA, USA) is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time, ultimately enhancing contact lens comfort. While studies have shown that Tangible Hydra-PEG technology can improve contact lens discomfort (CLD) in soft contact lens and gas permeable lens wearers, to our knowledge, no clinical research investigation has examined the benefits of this new coating on scleral lens wear in dry eye sufferers. As such, the aim of this study is to compare the CLD and DE symptoms of dry eye scleral lens wearers between Tangible Hydra-PEG treated scleral lens wear and untreated scleral lens wear. CLD and DE signs will also be assessed to corroborate our findings.

This will be the first randomized double masked cross-over study to examine CLD and DE symptoms of Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens wear in the dry eye patient population. Tangible Hydra-PEG treated scleral lenses can potentially minimize CLD and DE symptoms, ultimately improving outcomes for patients coping with dry eye disease. This study will provide new information about this innovative technology and help practitioners envisage rehabilitative options which will best optimize the quality of life of this important patient population.

03

Conditions studied

  • Dry Eye
  • Dry Eye Syndromes

Browse trials for

Keywords

  • Contact lens discomfort
  • Scleral lens
  • Tangible Hydra-PEG
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reduced tear film break up time (TBUT), a sign of dry eye disease and contact lens discomfort
  • Scleral lens wearer (at least 8 hours per day for at least 5 days per week and have had their habitual lenses no longer than 1 year). Scleral lenses wear will be defined as 15.00 mm to 19.00 mm inclusive.

Exclusion criteria

Exclusion Criteria:

  • Disorders that affect sensitivity (herpetic disease, severe diabetes mellitus)
  • Anatomic variations of the conjunctiva that can impair proper scleral lens fitting
  • Pregnancy
  • Best corrected Snellen visual acuity worse than 20/30 in either eye
  • Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration, keratoconus) which may significantly impact visual function.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treated followed by untreated

    Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).

    Device: Scleral lenses treated with Tangible Hydra-PEG · Device: Untreated scleral lenses

  • Experimental
    Untreated followed by treated

    Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).

    Device: Scleral lenses treated with Tangible Hydra-PEG · Device: Untreated scleral lenses

Interventions

  • DeviceScleral lenses treated with Tangible Hydra-PEG

    Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.

    Also known as: Tangible Hydra-PEG is a hydrophilic PEG-based lens coating

  • DeviceUntreated scleral lenses

    Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.

    Also known as: control

06

What researchers measure

Primary outcomes

  1. Ocular Surface Tear Breakup Time

    Tear breakup time of the ocular surface after wearing lenses

    Time frame: 30 days

  2. Corneal Fluorescein Staining

    Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses

    Time frame: 30 days

  3. Ocular Surface Disease Index (OSDI) Questionnaire

    Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).

    Time frame: 30 days

  4. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)

    Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.

    Time frame: 30 days

Secondary outcomes

  1. Tear Breakup Time Over the Surface of the Scleral Lens

    Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens

    Time frame: 30 days

  2. Lid Wiper Epitheliopathy

    Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.

    Time frame: 30 days

  3. Contact Lens-related Papillary Conjunctivitis

    Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis \[0 (normal) to 4 (severe)\] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.

    Time frame: 30 days

  4. Temporal Conjunctival Lissamine Green Staining

    Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).

    Time frame: 30 days

  5. Nasal Conjunctival Lissamine Green Staining

    Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).

    Time frame: 30 days

07

Results

Posted Jan 18, 2020

Participant flow

First Lens Type (30 Days)
Participant flow — First Lens Type (30 Days)
MilestoneHydra-PEG Treated Lenses Followed by Untreated LensesUntreated Lenses Followed by Hydra-PEG Treated Lenses
Started912
Completed811
Not completed11
Withdrew: Lost to follow-up11
Washout Period (7 Days)
Participant flow — Washout Period (7 Days)
MilestoneHydra-PEG Treated Lenses Followed by Untreated LensesUntreated Lenses Followed by Hydra-PEG Treated Lenses
Started811
Completed811
Not completed00
Second Lens Type (30 Days)
Participant flow — Second Lens Type (30 Days)
MilestoneHydra-PEG Treated Lenses Followed by Untreated LensesUntreated Lenses Followed by Hydra-PEG Treated Lenses
Started811
Completed811
Not completed00

Outcome measures

PrimaryOcular Surface Tear Breakup Time

Tear breakup time of the ocular surface after wearing lenses

Time frame:
30 days
Reported as:
Mean · seconds
Ocular Surface Tear Breakup Time
secondsHydra-PEG Treated Lens WearersUntreated Lens Wearers
Ocular Surface Tear Breakup Time3.81 ± 2.632.91 ± 2.14
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · t-test, 1 sided · p = <0.01Paired t-test comparison
PrimaryCorneal Fluorescein Staining

Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses

Time frame:
30 days
Reported as:
Mean · score on a scale
Corneal Fluorescein Staining
score on a scaleHydra-PEG Treated Lens WearersUntreated Lens Wearers
Corneal Fluorescein Staining0.92 ± 0.791.40 ± 1.05
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = <0.05 (Calculated p value was \<0.05.)Wilcoxon signed rank comparisons, one-sided
PrimaryOcular Surface Disease Index (OSDI) Questionnaire

Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).

Time frame:
30 days
Reported as:
Mean · OSDI score
Ocular Surface Disease Index (OSDI) Questionnaire
OSDI scoreHydra-PEG Treated Lens WearersUntreated Lens Wearers
Ocular Surface Disease Index (OSDI) Questionnaire28.24 ± 12.9035.10 ± 17.60
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · t-test, 1 sided · p = <0.01paired 1-sided t-test
PrimaryContact Lens Dry Eye Questionnaire-8 (CLDEQ-8)

Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.

Time frame:
30 days
Reported as:
Mean · CLDEQ-8 score
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)
CLDEQ-8 scoreHydra-PEG Treated Lens WearersUntreated Lens Wearers
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)11.89 ± 5.2617.30 ± 6.50
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = <0.01Wilcoxon signed rank comparison, one sided p value
SecondaryTear Breakup Time Over the Surface of the Scleral Lens

Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens

Time frame:
30 days
Reported as:
Mean · seconds
Tear Breakup Time Over the Surface of the Scleral Lens
secondsHydra-PEG Treated Lens WearersUntreated Lens Wearers
Tear Breakup Time Over the Surface of the Scleral Lens5.88 ± 5.174.75 ± 2.82
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · t-test, 1 sided · p = >0.05 (Calculated p value was \>0.05.)paired
SecondaryLid Wiper Epitheliopathy

Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.

Time frame:
30 days
Reported as:
Mean · score on a scale
Lid Wiper Epitheliopathy
score on a scaleHydra-PEG Treated Lens WearersUntreated Lens Wearers
Lid Wiper Epitheliopathy0.89 ± 0.761.41 ± 0.62
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = <0.05 (Calculated p value was \<0.05.)paired, 1-sided
SecondaryContact Lens-related Papillary Conjunctivitis

Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis \[0 (normal) to 4 (severe)\] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.

Time frame:
30 days
Reported as:
Mean · score on a scale
Contact Lens-related Papillary Conjunctivitis
score on a scaleHydra-PEG Treated Lens WearersUntreated Lens Wearers
Contact Lens-related Papillary Conjunctivitis0.89 ± 0.661.45 ± 0.51
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = <0.01paired, 1-sided
SecondaryTemporal Conjunctival Lissamine Green Staining

Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).

Time frame:
30 days
Reported as:
Mean · score on a scale
Temporal Conjunctival Lissamine Green Staining
score on a scaleHydra-PEG Treated Lens WearersUntreated Lens Wearers
Temporal Conjunctival Lissamine Green Staining0.95 ± 0.791.23 ± 1.03
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = <0.05 (Calculated p value was \<0.05.)paired, 1-sided
SecondaryNasal Conjunctival Lissamine Green Staining

Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).

Time frame:
30 days
Reported as:
Mean · score on a scale
Nasal Conjunctival Lissamine Green Staining
score on a scaleHydra-PEG Treated Lens WearersUntreated Lens Wearers
Nasal Conjunctival Lissamine Green Staining0.79 ± 0.711.03 ± 0.98
Statistical analysis
  • Hydra-PEG Treated Lens Wearers vs Untreated Lens Wearers · Wilcoxon (Mann-Whitney) · p = >0.05 (Calculated p value was \>0.05.)paired, 1-sided

Adverse events

Collected over Adverse event data were collected throughout the period of the study (a period of 79 days for each participant).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hydra-PEG Treated Lenses Followed by Untreated Lenses0/9 (0%)0/9 (0%)0/9 (0%)
Untreated Lenses Followed by Hydra-PEG Treated Lenses0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

All participants wore both the Hydra-PEG treated and untreated lenses in this crossover study, therefore the baseline characteristics are the same for both lens types.

Age, Continuous
Age, Continuous(years)Participants
Mean51.8 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Participants
Female16
Male3
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Participants
08

Study locations

3 sites
  • University of California, Davis
    Sacramento, California 95825, United States
  • Nova Southeastern University
    Fort Lauderdale, Florida 33314, United States
  • Illinois College of Optometry
    Chicago, Illinois 60616, United States
09

References and documents

Publications

  • Mickles CV, Harthan JS, Barnett M. Assessment of a Novel Lens Surface Treatment for Scleral Lens Wearers With Dry Eye. Eye Contact Lens. 2021 May 1;47(5):308-313. doi: 10.1097/ICL.0000000000000754. PubMed 33156128 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2019, 11 months.

Results were first posted in Jan 2020, 1 year after primary completion.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 11 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Jan 31, 2018
StartActual
Jan 30, 2018
Primary completionActual
Jan 4, 2019
CompletionActual
Jan 4, 2019
Results first posted
Jan 18, 2020
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03417505
Lead sponsor
Tangible Science
Collaborators
Nova Southeastern University, University of California, Davis, Illinois College of Optometry
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Jan 30, 2018
Primary completion
Jan 4, 2019
Completion
Jan 4, 2019
Results posted
Jan 18, 2020
Last update
Jan 18, 2020

Study contacts

Chandra Mickles, OD MS FAAO
principal investigator · Nova Southeastern University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion